<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809181</url>
  </required_header>
  <id_info>
    <org_study_id>ZJU-HSCT-AZA02</org_study_id>
    <nct_id>NCT04809181</nct_id>
  </id_info>
  <brief_title>Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients</brief_title>
  <official_title>Azacitidine in Combination With Venetoclax Treatment for Prevention of Relapse in MRD Positive Post Allogeneic Hematopoietic Stem Cell Transplantation Acute Myelogenous Leukemia/ Myelodysplastic Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhejiang Chinese Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo No. 1 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yinzhou Hospital Affiliated to Medical School of Ningbo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinhua Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Union hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with MRD-positive patients after AML/MDS allogeneic hematopoietic stem cell&#xD;
      transplantation, azacytidine combined with venetoclax may be effective in eliminating micro&#xD;
      residual diseases, reducing the risk of relapse, and ultimately improving long-term&#xD;
      survival.The primary purpose of this study was to explore an effective protocol to reduce the&#xD;
      risk of relapse in patients with MRD positive after allogeneic hematopoietic stem cell&#xD;
      transplantation for AML/MDS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The technology of Allogeneic Hematopoietic stem cell transplantation (allo-HSCT) has been&#xD;
      continuously improved, relpase is still the leading cause of death after allo-HSCT.&#xD;
      Monitoring of micro residual disease (MRD) after allogeneic HSCT provides a risk&#xD;
      stratification of relpase risk in patients after transplantation.There is an urgent need to&#xD;
      find an effective intervention plan for patients with MRD positive after transplantation, in&#xD;
      order to reduce the risk of relapse after transplantation and improve long-term survival.The&#xD;
      combination of demethylated drugs with venetoclax has shown promising results in clinical&#xD;
      trials in AML patients who cannot tolerate induction chemotherapy.In patients with&#xD;
      MRD-positive patients after AML/MDS allo-HSCT, azacytidine combined with venetoclax may be&#xD;
      effective in eliminating small residual diseases, reducing the risk of relapse, and&#xD;
      ultimately improving long-term survival.The primary purpose of this study was to explore an&#xD;
      effective protocol to reduce the risk of relapse in patients with MRD positive after&#xD;
      allo-HSCT for AML/MDS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">March 19, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 19, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapse-free survival</measure>
    <time_frame>2 year</time_frame>
    <description>relapse-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 year</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft-versus-host disease -free relapse-free survival</measure>
    <time_frame>2 year</time_frame>
    <description>graft-versus-host disease -free relapse-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of aGVHD</measure>
    <time_frame>100 days</time_frame>
    <description>cumulative incidence of aGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of cGVHD</measure>
    <time_frame>2 year</time_frame>
    <description>cumulative incidence of cGVHD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Hematologic Malignancy</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <arm_group>
    <arm_group_label>MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine in Combination With Venetoclax</intervention_name>
    <description>Azacitidine in combination with venetoclax</description>
    <arm_group_label>MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients between 18 years old and 65 years old.&#xD;
&#xD;
          2. Patients with AML or MDS diagnosed according to WHO diagnostic criteria.&#xD;
&#xD;
          3. Patients who received allogeneic hematopoietic stem cell transplantation and achieved&#xD;
             complete remission.&#xD;
&#xD;
          4. MRD was positive after transplantation, MFC &gt; 0.1% and / or fusion gene and gene&#xD;
             mutation (WT1 &gt; 0.6%, AML1-ETO &gt; 0.4%, others &gt;1%).&#xD;
&#xD;
          5. ECOG body status score 0-2.&#xD;
&#xD;
          6. Patients with expected survival time &gt;=3 months.&#xD;
&#xD;
          7. Good organ function level: ANC (neutrophil absolute value &gt;=1.0x10^9/L; PLT&#xD;
             &gt;=30x10^9/L; HB &gt;=80g/L; Tibil &lt;=1.5 ULN; ALT / AST &lt;=2.5 ULN; bun / Cr &lt;=1.5 ULN;&#xD;
             LVEF &gt;=50%).&#xD;
&#xD;
          8. Patients who have received any anti-tumor treatment (including radiotherapy,&#xD;
             chemotherapy, surgery or molecular targeted treatment) for more than 4 weeks from the&#xD;
             end of the previous treatment.&#xD;
&#xD;
          9. Patients with no GVHD and no previous history of 3 or more degrees of aGVHD. 10.&#xD;
             Patients who voluntarily participate in the clinical trial, understand the research&#xD;
             procedure and can sign the informed consent in writing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe cardiac insufficiency and EF lower than 60%; or patients with&#xD;
             severe arrhythmia who could not tolerate super pretreatment.&#xD;
&#xD;
          2. Patients with activity of aGVHD or extensive cGVHD.&#xD;
&#xD;
          3. Patients with BCR/ABL positive.&#xD;
&#xD;
          4. Patients who were previously known to be resistant to azacytidine or dessicabine or&#xD;
             venetoclax.&#xD;
&#xD;
          5. In patients with severe pulmonary insufficiency (obstructive and / or restrictive&#xD;
             ventilation disorders), the researchers evaluated the patients who could not tolerate&#xD;
             the super pretreatment scheme.&#xD;
&#xD;
          6. Patients with severe liver function impairment and liver function indexes (alt, TBIL)&#xD;
             more than 3 ULN were evaluated as intolerant of super pretreatment.&#xD;
&#xD;
          7. In patients with severe renal insufficiency, the renal function index (CR) is more&#xD;
             than 2 times of the upper limit of the normal value (ULN), or the 24-hour creatinine&#xD;
             clearance rate (CR) is less than 50ml / min, the researchers evaluated that they could&#xD;
             not tolerate the super pretreatment scheme.&#xD;
&#xD;
          8. In patients with severe active infection, the researchers evaluated that they could&#xD;
             not tolerate the pretreatment.&#xD;
&#xD;
          9. Patients who had allergic reactions or serious adverse reactions in the previous use&#xD;
             of pretreatment related drugs could not be included in the study.&#xD;
&#xD;
         10. Patients with hematological recurrence (bone marrow smear: proportion of primordial&#xD;
             cells &gt;=5%) or any extramedullary recurrence.&#xD;
&#xD;
         11. Other reasons why the researchers could not be selected.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Luo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affilaated Hospital of Medical School of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Luo, M.D.</last_name>
    <phone>+86057187233801</phone>
    <email>luoyijr@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yibo Wu, M.D.</last_name>
    <phone>+8619858876273</phone>
    <email>wuyibo7@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Luo, M.D.</last_name>
      <phone>+86057187233801</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Zhejiang University</investigator_affiliation>
    <investigator_full_name>Yi Luo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Allogeneic Hematopoietic stem cell transplantation</keyword>
  <keyword>Micro residual disease</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>Relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

